In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine

Australian Veterinary Journal

Volumn 93, Issue 1-2, 2015, Pages 40-45

  Bennie, C J M ^a   To, J L K ^a   Martin, P A ^a   Govendir, M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antibacterial drug combinations; Cats; Cefovecin; Clofazimine; Dogs; Rapidly growing mycobacteria

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CEFOVECIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DOXYCYCLINE; DRUG COMBINATION; ENROFLOXACIN; QUINOLONE DERIVATIVE; SULFANILAMIDE; SULFANILAMIDE DERIVATIVE; TRIMETHOPRIM;

ANIMAL; ANTIBIOTIC RESISTANCE; CAT; CAT DISEASES; COMPARATIVE STUDY; DOG; DOG DISEASES; DRUG COMBINATION; DRUG EFFECTS; IN VITRO STUDY; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM SMEGMATIS; STAPHYLOCOCCUS AUREUS; VETERINARY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CAT DISEASES; CATS; CEPHALOSPORINS; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DOG DISEASES; DOGS; DOXYCYCLINE; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; IN VITRO TECHNIQUES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM SMEGMATIS; STAPHYLOCOCCUS AUREUS; SULFANILAMIDES; TRIMETHOPRIM;

EID: 84922609360     PISSN: 00050423     EISSN: 17510813     Source Type: Journal    
DOI: 10.1111/avj.12279     Document Type: Article

References (36)

1. Malik R, Shaw SE, Griffin C etal. Infections of the subcutis and skin of dogs caused by rapidly growing mycobacteria. J Small Anim Pract 2004;45:485-494.
2. Malik R, Wigney DI, Dawson D etal. Infection of the subcutis and skin of cats with rapidly growing mycobacteria: a review of microbiological and clinical findings. J Feline Med Surg 2000;2:35-48.
3. Reppas G, Nosworthy P, Hansen T et al. Inguinal panniculitis in a young Tasmanian devil (Sarcophilus harrisii) caused by Mycobacterium mageritense. Aust Vet J 2010;88:197-200.
4. Adekambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol 2003;41:5699-5708.
5. Lloret A, Hartmann K, Pennisi MG etal. Mycobacterioses in cats: ABCD guidelines on prevention and management. J Feline Med Surg 2013;15:591-597.
6. Horne KS, Kunkle GA. Clinical outcome of cutaneous rapidly growing mycobacterial infections in cats in the south-eastern United States: a review of 10 cases (1996-2006). J Feline Med Surg 2009;11:627-632.
7. Alander-Damsten YK, Brander EE, Paulin LG. Panniculitis, due to Mycobacterium smegmatis, in two Finnish cats. J Feline Med Surg 2003;5:19-26.
8. Michaud A. The use of clofazimine as a treatment for Mycobacterium fortuitum in a cat. Feline Pract 1994;22:7-9.
9. Govendir M, Hansen T, Kimble B etal. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin. Vet Microbiol 2011;147:113-118.
10. Clinical and Laboratory Standards Institute. M24-A2 susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard. 2nd ed. CLSI, Wayne, PA, 2011.
11. Clinical and Laboratory Standards Institute. M100-S22 performance standards for antimicrobial susceptibility testing: 22nd informational supplement. CLSI, Wayne, PA, 2012.
12. Prescott JF. Sulfonamides, diaminopyrimidines and their combinations. In: Giguère S, Prescott JF, Baggot JD et al, editors. Antimicrobial therapy in veterinary medicine. 4th edn. Blackwell Publishing Asia, Carlton, 2006:249-262.
13. Ausina V, Condom MJ, Mirelis B etal. In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria. J Antimicrob Chemother 1986;29:951-952.
14. Clinical and Laboratory Standards Institute. VET01-S2 performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals: 2nd informational supplement. CLSI, Wayne, PA, 2013.
15. Griffith DE, Aksamit T, Brown-Elliott BA etal. An official ATSI/AISA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Resp Crit 2007;175:367-416.
16. Wallace RJ Jr, Jones DB, Wiss K. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei. Rev Infect Dis 1981;3:898-904.
17. Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian V, editor. Antibiotics in laboratory medicine. Lippincott Williams & Wilkins, Philadelphia, 2005:365-440.
18. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003;52:1-1.
19. Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002;15:716-746.
20. Govendir M, Norris JM, Hansen T etal. Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin. Vet Microbiol 2011;153:240-245.
21. Gottlieb S, Wigney DI, Martin PA etal. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones. Aust Vet J 2008;86:147-152.
22. Clinical and Laboratory Standards Institute. M31-A3 performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals: approved standard. 3rd edn. CLSI, Wayne, PA, 2008.
23. Clinical and Laboratory Standards Institute. VET01-A4 performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals: approved standard. 4th edn. CLSI, Wayne, PA, 2013.
24. Wiebe V, Hamilton P. Fluoroquinolone-induced retinal degeneration in cats. JAVMA 2002;221:1568-1571.
25. Gelatt KN, Van-Der-Woerdt A, Ketring KL etal. Enrofloxacin-associated retinal degeneration in cats. Vet Ophthalmol 2001;4:99-106.
26. King TC, Schlessinger D, Krogstad DJ. The assessment of antimicrobial combinations. Rev Infect Dis 1981;3:627-633.
27. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 1983;11:427-433.
28. MacGowan AP, Wootton M, Hedges AJ etal. A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative beta-lactam, aminoglycoside and fluoroquinolone. J Antimicrob Chemother 1996;38:193-203.
29. Rahal JJ Jr. Antibiotic combinations: the clinical relevance of synergy and antagonism. Medicine 1978;57:179-195.
30. Kothavade RJ, Dhurat RS, Mishra SN etal. Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria. Eur J Clin Microbiol Infect Dis 2013;32:161-188.
31. Stegemann MR, Sherington J, Blanchflower S. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharm Ther 2006;29:501-511.
32. Kaufman AC, Greene CE, Rakich PM etal. Treatment of localized Mycobacterium avium complex infection with clofazimine and doxycycline in the cat. J Am Vet Med Assoc 1995;207:457-459.
33. Malik R, Gabor L, Martin P etal. Subcutaneous granuloma caused by Mycobacterium avium complex infection in a cat. Aust Vet J 1998;76:604-607.
34. Sanchez MR. Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and d-penicillamine. Clin Dermatol 2000;18:131-145.
35. Shen G-H, Wu B-D, Hu S-T etal. High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010;35:400-404.
36. Malik R, Smits B, Reppas G etal. Ulcerated and nonulcerated nontuberculous cutaneous mycobacterial granulomas in cats and dogs. Vet Dermatol 2013;24:146-153.